2 Best ETFs ASX Investors Can Buy in October
Image source: Getty Images
If you’re looking for an easy way to invest your hard-earned money, exchange-traded funds (ETFs) might be the answer.
This is because ETFs give you the ability to invest in a large number of stocks at once, which can be a great way to build a diversified portfolio.
But which ETFs should you watch this month? Here are two popular ETFs that could be quality options right now:
BetaShares NASDAQ 100 ETF (ASX:NDQ)
The BetaShares NASDAQ 100 ETF might be worth considering in October. Especially given its incredibly poor performance in September, which left it trading around its lowest levels of the year.
This ETF gives investors access to the top 100 non-financial stocks on the popular NASDAQ stock exchange. This includes Alphabet, Amazon, Apple, Meta, Microsoft, Netflix, Nvidia, and Tesla.
BetaShares also points out that with a strong focus on technology, the ETF provides investors with diversified exposure to a high growth potential sector that is underrepresented in the Australian equity market.
ETFS S&P Biotech ETF (ASX: CURE)
Another ETF investors should consider in October is the ETFS S&P Biotech ETF.
This ETF offers investors exposure to the US biotech sector. The ETFS notes that these are companies engaged in the research, development and manufacture of products based on genetic analysis and genetic engineering. This includes the development of immunotherapy treatments and vaccines to treat human diseases.
Its holdings include ChemoCentryx, Global Blood Therapeutics, and Twist Bioscience, among others.
A big ETF fan is Felicity Thomas of Shaw & Partners. She recently said Live Cable:
I like to buy long-term ETFs. We have an aging population, and what is the most important thing in the world? Your health. Biotechnology, healthcare and life sciences are where you want to invest in the next two decades.